


A Great Leap for Intestinal Research: 20 YEARS AND BEYOND

Curriculum Vitae

Personal Information	
Title (i.e. Pf., Dr., etc.)	Professor
Name (First name Middle name Last name)	Byong Duk Ye
Degree (i.e. MD, Msc, PhD, etc.)	MD, MPH, PhD
Country	Korea
Affiliation	Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine
	
Educational Background	
1991–1993: Pre-medical course, College of Natural Science, Seoul National University, Seoul, Korea	
1993–1997: College of Medicine, Seoul National University, Seoul, Korea	
2002–2005: Graduate School of Public Health (Master degree), Seoul National University, Seoul, Korea	
2005–2007: Graduate School of Medicine (PhD degree), Seoul National University, Seoul, Korea	
Professional Experience	
Sep 2021–Present: Director, Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea	
2007–Present: Professor, Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea	
2014–2016: Visiting Scholar, Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA	
Professional Organizations	
APR 2021–Present: Director, Scientific Committee, Korean Association for the Study of Intestinal Diseases (KASID)	
APR 2019–APR 2021: Director, International Academic Exchange Committee, Korean Association for the Study of Intestinal Diseases (KASID)	

A Great Leap for Intestinal Research: 20 YEARS AND BEYOND

Main Scientific Publications

1. Hong SW, Ye BD, Cheon JH, et al. Clinical Features and Long-term Prognosis of Crohn's Disease in Korea: Results from the Prospective CONNECT Study. *Gut Liver*. 2022 Mar 24. doi: 10.5009/gnl210299 (Corresponding author).
2. Seo M, Kim Y, Ye BD, et al. Positron emission tomography imaging of system xc- in immune cells for assessment of disease activity in mice and patients with inflammatory bowel disease. *J Nucl Med* 2022 Jan 27; jnumed.121.263289. doi: 10.2967/jnumed.121.263289 (Co-first author).
3. Oh K, Oh EH, Noh SM, et al. Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy. *Clin Transl Gastroenterol* 2022;13:e00442 (Corresponding author).
4. Hong HS, Jung J, Park SH, et al. Seroprevalence of viral infectious diseases and associated factors in Korean patients with inflammatory bowel diseases. *Korean J Intern Med* 2022;37:73-84 (Corresponding author).
5. Ryu HH, Chang K, Kim N, et al. Insufficient vaccination and inadequate immunization rates among Korean patients with inflammatory bowel diseases. *Medicine (Baltimore)*. 2021;100:e27714 (Corresponding author).
6. Lee JM, Wei SC, Lee KM, et al. Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease. *Gut Liver* 2021 Oct 1. doi: 10.5009/gnl210081 (Corresponding author).
7. Ye BD, Cheon JH, Song KH, et al. The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study. *Therap Adv Gastroenterol* 2021;14:17562848211024769 (Corresponding author).
8. Ye BD, Hong SN, Seo SI, et al. Changes in the Long-term Prognosis of Crohn's Disease between 1986 and 2015: The Population-Based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study. *Gut Liver* 2022;16:216-227 (First author).
9. Kim K, Jo KW, Shim TS, et al. Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors. *Front Med (Lausanne)* 2021 May 21;8:670242 (Corresponding author).
10. Jung S, Ye BD, Lee HS, et al. Identification of Three Novel Susceptibility Loci for Inflammatory Bowel Disease in Koreans in an Extended Genome-Wide Association Study. *J Crohns Colitis* 2021;15:1898-1907 (Co-first author).
11. Schreiber S, Ben-Horin S, Jaroslaw Leszczyszyn J, et al. Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. *Gastroenterology* 2021;160:2340-2353 (Corresponding author).

IMKASID 2022

COMMEMORATING
THE 20th ANNIVERSARY OF KASID

THE 5th INTERNATIONAL MEETING ON INTESTINAL DISEASES IN CONJUNCTION WITH
THE ANNUAL CONGRESS OF THE KOREAN ASSOCIATION FOR THE STUDY OF INTESTINAL DISEASES

MAY 12 THU - 14 SAT, 2022 / BEXCO, Busan [IN PERSON & VIRTUAL EVENT ▶▶](#)

A Great Leap for Intestinal Research: 20 YEARS AND BEYOND

12. Kim J, Yoon H, Kim N, et al. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. *Inflamm Bowel Dis* 2021;27(12):1931-1941 (Corresponding author).
13. Lee SH, Walshe M, Oh EH, et al. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment. *Inflamm Bowel Dis* 2021;27:1452-1461 (Corresponding author).
14. Shin JY, Park HM, Lee MY, et al. Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study. *Gut Liver* 2021;15:867-877 (Corresponding author).
15. Song EM, Oh EH, Hwang SW, et al. Comparison of outcomes of cyclosporine A and infliximab for steroid-refractory acute severe ulcerative colitis. *J Gastroenterol Hepatol* 2021;36:2463-2470 (Corresponding author).
16. Noh SM, Oh EH, Park SH, et al. Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy. *J Crohns Colitis* 2020;14:1231-1240 (Corresponding author).
17. Hong SW, Kim YG, Ye BD, et al. An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory disease. *Immunotherapy* 2020;12:609-623 (Corresponding author).
18. Oh EH, Kim J, Ham N, et al. Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study. *Gut Liver* 2020;14:347-356 (Corresponding author).
19. Ye BD, Kim BM, Jung S, et al. Association of FUT2 and ABO with Crohn's disease in Koreans. *J Gastroenterol Hepatol* 2020;35:104-109 (Co-first author).
20. Lee HS, Kim K, Jung S, et al. Effects of smoking on the association of human leukocyte antigen with ulcerative colitis. *J Gastroenterol Hepatol* 2019;34:1777-1783 (Corresponding author).
21. Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. *Lancet* 2019;393:1699-1707 (First author).